source
- Pfizer delays patent cliff for blockbuster VyndamaxPfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a hear…Endpoints · 3mo ago↗ source
- Hikma and Amarin's generic drug case heads to Supreme Court argumentsWhen the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications o…Endpoints · 3mo ago↗ source
- Rocket's PRV goes for $180M; Oruka targets $500M offeringRocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...